Roche Holding AG (LON:0QQ6)
London · Delayed Price · Currency is GBP · Price in CHF | Market Cap | 229.73B |
| Revenue (ttm) | 58.27B |
| Net Income (ttm) | 8.65B |
| Shares Out | n/a |
| EPS (ttm) | 10.78 |
| PE Ratio | 26.55 |
| Forward PE | 15.17 |
| Dividend | 8.49 (2.80%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 14,233 |
| Average Volume | 11,197 |
| Open | 302.00 |
| Previous Close | 299.00 |
| Day's Range | 300.80 - 303.40 |
| 52-Week Range | 244.60 - 333.20 |
| Beta | 0.14 |
| RSI | 70.34 |
| Earnings Date | Oct 20, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial numbers in CHF Financial StatementsNews
FDA Approves Roche's Tecentriq for Lung Cancer Treatment
FDA Approves Roche's Tecentriq for Lung Cancer Treatment
Roche's Genentech gets FDA nod for lung cancer treatment
FDA approves Roche's Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab ...
Change in the Roche Board of Directors
Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Dr. Claudia Süssmuth Dyckerhoff has decided not to stand for re-election as a member of the Roche Board of Directors at ...
FDA Approves Genentech's Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentr...
Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR
(RTTNews) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes a cash payment of $14.50 per s...
Trade treaty kicks in, Swiss govt seeks investment pact
EFTA Bloc nations pledged $100 billion investments in India under a new trade deal, with Switzerland seeking a bilateral investment treaty and Liechtenstein a double taxation avoidance agreement. Phar...
Roche Initiates Tender Offer for 89bio (ETNB) in $3.5B Acquisition
Roche Initiates Tender Offer for 89bio (ETNB) in $3.5B Acquisition
Roche begins tender offer for 89bio as part of acquisition
Roche launches $3.5B tender offer for 89bio shares, including milestone payments. Learn key deal details and deadlines.
Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash
Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. (89bio) (NASDAQ: ETNB) ...
Novo Nordisk, Roche gain upgrades from HSBC
HSBC upgrades Novo Nordisk and Roche to buy, citing strong drug pipelines and growth prospects. Read more here.
Swiss pharma companies eye follow up to Pfizer-US pricing deal, business lobby says
GENEVA (Reuters) -Swiss drugmakers could strike their own deals with the U.S. after President Donald Trump's push to lower prescription drug prices led to an accord with Pfizer in exchange for tariff ...
Roche's Troponin T Test Offers New Level Of Accuracy Critical For Diagnosing Heart Attacks
(RTTNews) - Roche (RHHBY) Tuesday announced the primary results from the TSIX Study Program, which evaluated the performance of its new sixth-generation high-sensitivity Troponin T test for diagnosing...
Labcorp partners with Roche to advance digital pathology and AI integration
Labcorp Collaborates With Roche To Implement VENTANA DP 600 And DP 200 Slide Scanners
(RTTNews) - Labcorp (LH) announced a collaboration with Roche to implement the company's FDA-cleared VENTANA DP 600 and DP 200 slide scanners. The investment enables pathologists to diagnose patients ...
Data show Roche's sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks
Basel, 30 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the primary results from the TSIX Study Program, which evaluated the performance of its new sixth-generation high-sensitivity Tr...
Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026
GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. Luke will succeed the current CEO, Dame Emma Wal...
Amneal seeks FDA nod for generic targeting Xolair marketed by Roche and Novartis
Roche points to U.S. plans after Trump pharma tariff announcement
Switzerland's Roche on Friday pointed to the fact that one of its U.S. units broke ground on a new facility in August and that the pharma company had pledged major U.S. investments after President Don...
Kodiak gains as Barclays upgrades on Roche data for eye disease drug
Kodiak Sciences (KOD) stock gains as Barclays upgrades the company, citing a positive read-through from a recent trial readout from Roche (RHHBY). Read more here.
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial
Roche Pharmaceuticals' CEO told investors she was "serious" about the goal of becoming a top 3 obesity player. The drugmaker's CT-388 weight loss injection is entering a phase III trial, marking the l...
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025
Basel, 24 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presents new data for OCREVUS® (ocrelizumab) and the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib at the 41st Con...
Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus® (ocrelizumab) and the investigational Bruton's tyrosin...
Roche's Giredestrant: A Ray Of Hope On A Cloudy Horizon?
Swiss pharmaceutical and diagnostics giant Roche Holding has finally released some positive news about its oral breast cancer drug giredestrant, which...